Publication of Phase 1 data on SDC-1801 in BJCP

Sareum Holdings PLC

22 June 2026

 

Sareum Holdings PLC

("Sareum" or the "Company")

Publication of Phase 1 clinical data on SDC-1801 in British Journal of Clinical Pharmacology 

·    SDC-1801 demonstrated a well-tolerated safety profile with clear TYK2/JAK1 target engagement and reinforces the Company's confidence in SDC-1801's potential as a best-in-class, once-daily oral therapy for autoimmune diseases

·    PK/PD data from the Phase 1 trial informed the ongoing toxicology programme with a complete Phase 2‑enabling regulatory package anticipated by year-end

Cambridge, UK, 22 June 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces the publication of the full dataset from the Phase 1 clinical trial of its lead asset, SDC-1801, in the peer-reviewed British Journal of Clinical Pharmacology.  

The paper, titled 'First-in-human, phase I, randomised, safety, pharmacokinetic, food-effect, and pharmacodynamic study of a tyrosine kinase 2/janus kinase 1 inhibitor, SDC-1801', presents the findings from a randomised, double-blind, placebo-controlled study conducted in 95 healthy adult participants. The paper confirms the results previously disclosed by the Company with comprehensive clinical and pharmacological characterisation of SDC-1801.

Key results include:

·    SDC-1801 was well tolerated across all doses tested, from 5-150 mg, with no deaths and no treatment-related serious adverse events

·    Pharmacokinetics (PK) analysis demonstrated a half-life of approximately 15-27 hours, supporting once or twice-daily oral dosing

·   Computational PK modelling demonstrated that SDC-1801 at 70mg twice-daily achieved blood exposure levels comparable to brepocitinib, a clinically validated dual TYK2/JAK1 inhibitor, at 100mg once-daily without the side effects observed with brepocitinib at this exposure level

·    Pharmacodynamic biomarker analysis provided evidence of sustained target engagement of both TYK2 and JAK1

The PK data from the Phase 1 trial informed the ongoing Phase 2-enabling formulation programme to optimise the capsule, aimed at improving drug release at higher doses and reducing the capsule burden in future clinical trials. Formulation optimisation and the ongoing toxicology programme is being undertaken using the Company's existing cash resources, with a complete Phase 2‑enabling regulatory package anticipated by year-end.

Dr John Reader, Chief Scientific Officer of Sareum, commented: "The publication of the Phase 1 data in the British Journal of Clinical Pharmacology provides independent scientific validation of the strong clinical profile of SDC-1801, including good tolerability, a pharmacokinetic profile consistent with once-daily oral dosing, and clear evidence of target engagement through dose-dependent reductions in established inflammatory biomarkers."

"These biomarker findings are predictive of SDC-1801's potential efficacy in patients and reinforce our confidence in SDC-1801's potential as a differentiated therapy for autoimmune diseases. With the Phase 2-enabling toxicology programme well underway, we are focused on translating this clinical evidence into the next stage of development."

The full paper is available via the British Journal of Clinical Pharmacology here: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70642

- ENDS-

For further information, please contact: 

Sareum Holdings plc Stephen Parker, Executive Chairman	01223 497700 [e-mail]
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman Singer Capital Markets (Joint Corporate Broker)  Russell Cook/Patrick Weaver	020 7409 3494 020 7496 3000
Oberon Capital (Joint Corporate Broker) Mike Seabrook / Nick Lovering	020 3179 5300
ICR Healthcare (Financial PR) Jessica Hodgson / Lisa Lam / Tom Daniel	020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease

The Company holds the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

 

END